Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
20-jaars risico op terugkeer borstkanker na hormonale therapie
nov 2017 | Borstkanker